Skip to Main Content

CareDx, Inc. (CDNA) Securities Fraud Violations Class Action Lawsuit

View Complaint
COMPANY         CareDx, Inc.
COURT United States District Court for the Northern District of California
CASE NUMBER 22-cv-03023
JUDGE Honorable Trina L. Thompson
CLASS PERIOD February 24, 2021 through May 5, 2022
SECURITY TYPE  Class A Common Stock

Case Background:

This is a federal securities fraud class action lawsuit on behalf all persons and entities that purchased or otherwise acquired CareDx, Inc. (“CareDx”) (NASDAQ: CDNA) common stock between February 24, 2021 and May 5, 2022, both dates inclusive (the “Class Period”).

The complaint alleges that, throughout the Class Period, the Defendants mislead investors and/or failed to disclose that: (1) the Defendants had engaged in a variety of improper and illegal schemes to inflate testing services revenue and demand, including pushing a surveillance protocol through inaccurate marketing materials, offering extravagant inducements or kickbacks to physicians and other providers, and improperly bundling expensive testing services with other blood tests as part of the RemoTraC service; (2) these practices, and others, subjected CareDx to an undisclosed risk of regulatory scrutiny; (3) these practices rendered CareDx’s testing services revenue reported throughout the Class Period artificially inflated; and (4) as a result, the defendants’ positive statements about CareDx’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Current Status of Case:

On July 23, 2025, the Court issued an Order granting Preliminary Approval of the Class Action Settlement and scheduled a Final Settlement Hearing for December 2, 2025.  This action is ongoing. 

Please be advised that the deadline to file a claim is November 12, 2025. You may find additional information regarding the terms of the settlement and claim filing process at  www.CareDxSecuritiesLitigation.com or by contacting the claims administrator, A.B. Data, Ltd. at 877-423-0707.

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP:  Jon Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com.  If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.

Please complete this form relating to your transactions for CareDx, Inc. (NASDAQ: CDNA) common stock between February 24, 2021, and May 5, 2022, inclusive (the “Class Period”).

You may also contact Jon Naji, Esq. (484) 270-1453; or you may submit your information via email at info@ktmc.com; or you may click here to print a PDF of this form.

SUBMIT YOUR INFORMATION
* Denotes required field
Date
# of Shares
Price per Share
Date
Principal Amount
Amount Paid
Series or CUSIP
Date
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of CareDx, Inc. prior to the Class Period?
Are you a current or former employee of CareDx, Inc.?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email